Simulations Plus, Inc.
SLP
NASDAQ·Technology·Software - Application·Mkt cap $372.7M
$18.43
▲ +0.05%
P/E
46.12
Mkt Cap
$372.7M
52-Wk Range
$11.09–$21.01
52-Week Range
$11.09 - $21.01
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 30.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary AI/ML-powered simulation technology with 28-year development history and regulatory validation
- Integrated software ecosystem covering drug discovery through clinical development phases
- Strong relationships with FDA and global regulatory agencies, enabling faster regulatory approvals
- Specialized expertise in mechanistic modeling and quantitative systems pharmacology with limited direct competitors
- Recurring revenue model through software licensing, consulting services, and contract research
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Steady revenue growth (13% YoY)
Value
Fairly valued vs Healthcare IT & Services peers
Momentum
Strong
+15.8% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SLP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 9, 2026
Reported EPS of $0.30 vs $0.23 consensus (+29.0% surprise). Revenue of $21.9M vs $20.9M expected (+4.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+29.0%
Revenue trend · last 8Q
—
—
+23%
+10%
-6%
-3%
+8%
+7%
Q4 24
Q1 24
Q2 25
Q3 25
Q4 25
Q1 25
Q2 26
Q3 26
$18.7M
$18.9M
$22.4M
$20.4M
$17.5M
$18.4M
$24.3M
$21.9M
Margins · last 8Q
Gross
69.1%
Operating
20.6%
Profit
16.3%
Wall Street consensus
3 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Jun 18, 2026
vs Industry
How SLP stacks vs Software - Application
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related